Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MASP2 | O00187 | 4/20 | 0.42 |
| ▸ | F10 | P00742 | 1/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.37 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 2/20 | 0.36 |
| ▸ | PPARA | Q07869 | 2/20 | 0.36 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.36 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 2/20 | 0.35 |
| ▸ | CTSS | P25774 | 2/20 | 0.35 |
| ▸ | PPARD | Q03181 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5041100 | 0.91 | MASP2 (0.43) | MASP2F10KLKB1PPARGPPARA | |
| SCHEMBL5045462 | 0.87 | F10 (0.44) | MASP2F10 | |
| SCHEMBL5043460 | 0.87 | MASP2 (0.42) | MASP2F10KLKB1S1PR3 | |
| SCHEMBL5037329 | 0.86 | MASP2 (0.47) | MASP2F10KLKB1 | |
| SCHEMBL5045182 | 0.86 | SLC1A3 (0.41) | F10SCN5ASCN9AKLKB1PPARG | |
| SCHEMBL5045183 | 0.86 | SLC1A3 (0.41) | F10SCN5ASCN9AKLKB1PPARG | |
| SCHEMBL5043044 | 0.85 | PLAU (0.37) | F10KLKB1PPARGPPARAEGLN2 | |
| SCHEMBL5043049 | 0.85 | PLAU (0.37) | F10KLKB1PPARGPPARAEGLN2 | |
| SCHEMBL6068687 | 0.85 | MAPK14 (0.43) | MASP2F10KLKB1PPARGPPARA | |
| SCHEMBL6068661 | 0.84 | MASP2 (0.40) | MASP2F10KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1567498-B1 | MANDELIC ACID DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-01-23 | — | — | EP | disclosed |
| US-7129238-B2 | Mandelic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-10-31 | — | — | US | disclosed |
| US-20040122057-A1 | Novel mandelic acid derivatives | HOFFMANN-LA ROCHE INC. | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122057-A1 | Novel mandelic acid derivatives | F7, F11, F9 | MASP2 370/4885F10 8/4885SCN5A 2957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.